Acrivon Therapeutics annual return on equity
2022
2023
2024
2025
Acrivon Therapeutics Return on Equity (ROE) Growth & History (ACRV)
Acrivon Therapeutics's return on equity was −53.86% for fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −53.86% | +0.21 pp |
| 2024 | 2024-12-31 | −54.07% | −12.66 pp |
| 2023 | 2023-12-31 | −41.41% | +1.09 pp |
| 2022 | 2022-12-31 | −42.50% | — |
Acrivon Therapeutics quarterly return on equity
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −19.72% | −5.88 pp |
| Q1 2026 | 2026-03-31 | −18.31% | −6.63 pp |
| Q4 2025 | 2025-12-31 | −15.75% | −3.53 pp |
| Q3 2025 | 2025-09-30 | −13.43% | −2.56 pp |
| Q2 2025 | 2025-06-30 | −13.85% | −2.24 pp |
| Q1 2025 | 2025-03-31 | −11.67% | +2.71 pp |
| Q4 2024 | 2024-12-31 | −12.22% | +2.63 pp |
| Q3 2024 | 2024-09-30 | −10.87% | −0.80 pp |
| Q2 2024 | 2024-06-30 | −11.60% | −2.62 pp |
| Q1 2024 | 2024-03-31 | −14.39% | −6.68 pp |
| Q4 2023 | 2023-12-31 | −14.85% | −0.54 pp |
| Q3 2023 | 2023-09-30 | −10.07% | — |
| Q2 2023 | 2023-06-30 | −8.99% | — |
| Q1 2023 | 2023-03-31 | −7.71% | — |
| Q4 2022 | 2022-12-31 | −14.30% | — |
Acrivon Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Acrivon Therapeutics's return on equity decreased from −42.50% to −53.86%, a change of −11.36 percentage points. The latest reported quarter, Q2 2026, shows −19.72%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics source filings ↗